Results 41 to 50 of about 3,878 (166)

Lifesaving Compassionate‐Use of Sotatercept in a 12‐Year‐old With Idiopathic Pulmonary Arterial Hypertension

Pulmonary Circulation, Volume 16, Issue 2, April 2026.
ABSTRACT Pediatric idiopathic pulmonary arterial hypertension (IPAH) refractory to maximal medical therapy is associated with high morbidity and mortality, and therapeutic options remain limited. We describe a 12‐year‐old girl with end‐stage IPAH who developed acute decompensated right heart failure despite triple combination therapy, including high ...
Weronika Pelczar‐Płachta, Rafał Surmacz, Waldemar Bobkowski   +2 more
wiley   +1 more source

The effects of levosimendan in patients undergoing transcatheter aortic valve replacement- a retrospective analysis

Frontiers in Pharmacology, 2022
Background: Aortic stenosis (AS) increases left ventricular afterload, leading to cardiac damage and heart failure (HF). Transcatheter aortic valve replacement (TAVR) is an effective therapy for AS.
Zhenyan Zhao, Zhen Meng, Zhen Meng, Guangyuan Song, Chunrong Wang, Sheng Shi, Jie Zhao, Hongliang Zhang, Moyang Wang, Guannan Niu, Zheng Zhou, Jianhui Wang, Yongjian Wu   +12 more
doaj   +1 more source

Mortality Predictions Including Pre‐Admission Functional Status in ICU Patients With Delirium—A Substudy of the AID‐ICU Trial

Acta Anaesthesiologica Scandinavica, Volume 70, Issue 4, April 2026.
ABSTRACT Purpose Pre‐admission functional status affects patients' ability to overcome the deteriorating effects of acute critical illness. We aimed to develop a clinical prediction model for 90‐day and 1‐year mortality based on pre‐admission data, including functional status, in adult delirious ICU patients. Methods We included participants randomized
Lone M. Poulsen, Andreas W. Rosen, Nina C. Andersen‐Ranberg, Camilla B. Mortensen, Anders Perner, Stine Estrup, Bodil S. Rasmussen, Ole Mathiesen   +7 more
wiley   +1 more source

Levosimendan, a Promising Pharmacotherapy in Cardiogenic Shock: A Comprehensive Review

European Cardiology Review
Cardiogenic shock (CS) is a critical condition with high mortality rate, as the current management of CS presents significant challenges. Exploration of more effective therapies is necessitated.
Hendri Susilo, Fan Maitri Aldian, Citrawati Dyah Kencono Wungu, Mochamad Yusuf Alsagaff, Henry Sutanto, Chaq El Chaq Zamzam Multazam   +5 more
doaj   +1 more source

Effect of levosimendan on prognosis in adult patients undergoing cardiac surgery: a meta-analysis of randomized controlled trials

Critical Care, 2017
Background Small trials suggest that levosimendan is associated with a favorable outcome in patients undergoing cardiac surgery. However, recently published larger-scale trials did not provide evidence for a similar benefit from levosimendan.
Qi-Hong Chen, Rui-Qiang Zheng, Hua Lin, Jun Shao, Jiang-quan Yu, Hua-Ling Wang   +5 more
doaj   +1 more source

From Thrombolysis to Transplant: Navigating the Storm of Delayed STEMI and Cardiogenic Shock

Clinical Case Reports, Volume 14, Issue 3, March 2026.
ABSTRACT Delayed STEMI presentation can cause extensive myocardial necrosis, left ventricular thrombus, cardiogenic shock, and progression to end‐stage heart failure despite reperfusion. Early recognition and timely transfer to specialized shock centers are critical.
Syed Rafay Hussain Zaidi, Muhammad Sheraz Hameed, Muhammad Ahsan, Hamza Ishfaq, Ali Iqbal, Azka Mirza, Sadia Rekhum, Muhammad Sohaib Alvi, Muhammad Usama Naveed   +8 more
wiley   +1 more source

İleri kalp yetersizliği hastalarında levosimendanın eritrosit dağılım genişliği üzerine etkisi

Genel Tıp Dergisi, 2015
Amaç: Levosimendan dekompanse kalp yetersizliğinde kullanılan, olumlu hemodinamik etkileri de olan pozitif inotropik bir ilaçtır. Bu çalışmanın amacı levosimendan tedavisi almış ileri kalp yetersizliği hastalarının tedavi öncesi ve sonrası eritrosit ...
Ahmet Gürel, Niyazi Güler, Murat Aydın, Şeref Alpsoy, Aydın Akyüz, Dursun Çayan Akkoyun   +5 more
doaj  

Inhibition of reverse-mode sodium-calcium exchanger activity and apoptosis by levosimendan in human cardiomyocyte progenitor cell-derived cardiomyocytes after anoxia and reoxygenation. [PDF]

PLoS ONE, 2014
Levosimendan, a known calcium sensitizer with positive inotropic and vasodilating properties, might also be cardioprotective during ischemia-reperfusion (I/R) insult. Its effects on calcium homeostasis and apoptosis in I/R injury remain unclear. Na(+)/Ca(
Ping-Chun Li, Ya-Chi Yang, Guang-Yuh Hwang, Lung-Sen Kao, Ching-Yuang Lin   +4 more
doaj   +1 more source

Biventricular Impella Support for Ventricular Tachycardia Ablation in a Patient With Severe Dilated Cardiomyopathy

Clinical Case Reports, Volume 14, Issue 3, March 2026.
VT ablation with percutaneous biventricular Impella support in a patients with non‐ischemic dilated cardiomyopathy and severe biventricular failure. Segmented Inheart CT, angulation a.p. (a) and LAO (c). Segmentation revealed the prior ablation site (blue arrow) and extensive intramural fibrotic tissue (asterisk).
Madeleine Tydecks, Theresa Reiter, Gabriele Hessling, Isabel Deisenhofer, Mohammad Al Fayad   +4 more
wiley   +1 more source

Does Levosimendan hasten veno-arterial ECMO weaning? A propensity score matching analysis

Annals of Intensive Care
Background Preliminary evidence from small, single-center studies suggests levosimendan may improve the likelihood of successful venoarterial extracorporeal membrane oxygenation (VA-ECMO) weaning in patients with cardiogenic shock.
Nicolas Paulo, Antoine Kimmoun, David Hajage, Pierre Hubert, David Levy, Marc Pineton de Chambrun, Juliette Chommeloux, Ouriel Saura, Grégoire Del Marmol, Quentin Moyon, Guillaume Hékimian, Melchior Gautier, Charles Edouard Luyt, Guillaume Lebreton, Bruno Levy, Alain Combes, Matthieu Schmidt   +16 more
doaj   +1 more source